Fusion Pharmaceuticals, Pepscan collaborate on radiopharmaceutical therapies

By The Science Advisory Board staff writers

January 12, 2022 -- Fusion Pharmaceuticals has entered into a strategic research collaboration with Pepscan Therapeutics to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumors. Radiopharmaceuticals are created using targeting molecules such as antibodies, small molecules, and peptides.

Fusion is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Under the agreement with Pepscan, Fusion has global rights to develop and commercialize any peptides discovered during the collaboration.

Fusion also announced the nomination of its targeted alpha therapy (TAT) candidate under the company's collaboration agreement with AstraZeneca. TAT utilizes Fusion's fast-clear linker technology to radiolabel an AstraZeneca-owned bispecific antibody with the alpha-emitting isotope actinium-225. Both companies will jointly develop the novel TAT through a phase I study.

Under the terms of the collaboration agreement, Fusion will be operationally responsible for preclinical development through first-in-human studies, while AstraZeneca will be responsible for subsequent clinical development. The companies will share costs equally through clinical development. Investigational new drug-enabling studies are ongoing, according to the firms.

Financial details of the collaborations were not disclosed.

Copyright © 2022 scienceboard.net

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter